(Z)-3-methylhex-3-ene-2,5-dione | 97204-34-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (Z)-3-methylhex-3-ene-2,5-dione
• CAS: 97204-34-7
• 化学式: C₇H₁₀O₂
• 分子量: 126.155
• InChiKey: SGWFXGZCQBUONH-PLNGDYQASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (Z)-3-methylhex-3-ene-2,5-dione 在 间氯过氧苯甲酸 作用下， 生成 Acetic acid (Z)-2-methyl-3-oxo-but-1-enyl ester
  参考文献：
  名称：

  呋喃的氧化II。呋喃在分子内狄尔斯-阿尔德反应中作为掩盖的亲二烯体的用途

  摘要：

  使用间氯过氧苯甲酸对链二烯基呋喃进行化学选择性氧化，得到的三烯经过分子内Diels-Alder环加成至氢化茚。

  DOI：

  10.1016/s0040-4039(00)99046-4
• 作为产物：
  描述：

  2,3,5-三甲基呋喃 在 间氯过氧苯甲酸 作用下， 生成 (Z)-3-methylhex-3-ene-2,5-dione
  参考文献：
  名称：

  呋喃的氧化II。呋喃在分子内狄尔斯-阿尔德反应中作为掩盖的亲二烯体的用途

  摘要：

  使用间氯过氧苯甲酸对链二烯基呋喃进行化学选择性氧化，得到的三烯经过分子内Diels-Alder环加成至氢化茚。

  DOI：

  10.1016/s0040-4039(00)99046-4

文献信息

• Purine analogs having HSP90-inhibiting activity
  申请人：Kasibhatla Srinivas Rao

  公开号：US20080125446A1

  公开（公告）日：2008-05-29

  Novel purine compounds and tautomers and pharmaceutically acceptable salts thereof are described, as are pharmaceutical compositions comprising the same, complexes comprising the same, e.g., HSP90 complexes, and methods of using the same.

  本发明涉及新型嘌呤化合物及其互变异构体和药学上可接受的盐，还涉及包含它们的药物组合物、包含它们的复合物，例如HSP90复合物，以及使用它们的方法。
• USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS
  申请人：Franklin Richard

  公开号：US20120202756A1

  公开（公告）日：2012-08-09

  The present invention relates to prodrugs of a wide variety of drugs and pharmaceutical compositions containing such prodrugs. Methods for minimizing locally mediated (from within the gut lumen) adverse gastrointestinal events associated with the underivatised drug and increasing the sustainment of plasma drug levels with the aforementioned prodrugs are also provided. Thus, the present invention relates to the use of prodrugs of a wide diversity of drugs (other than opioids) to transiently inactivate them and so reduce directly, locally mediated adverse gastrointestinal (GI) side-effects normally evident after administration of the parent compound. Additionally, such prodrugs may confer improved pharmacokinetics.

  本发明涉及各种药物的前药和含有这些前药的制药组合物。还提供了一种方法，用于最小化与未衍生药物相关的局部介导（来自肠腔内）不良胃肠事件，并使用上述前药增加血浆药物水平的持续性。因此，本发明涉及使用各种药物（除阿片类药物外）的前药，以短暂地使它们失活，从而减少通常在给予原始化合物后出现的直接、局部介导的不良胃肠（GI）副作用。此外，这些前药可能提供改善的药代动力学。
• CANNABINERGIC NITRATE ESTERS AND RELATED ANALOGS
  申请人：Northeastern University

  公开号：US20160002195A1

  公开（公告）日：2016-01-07

  The present technology relates to novel cannabinergic nitrate esters and related analogs, process of preparation, pharmaceutical compositions and their methods of use as medicaments, pharmacological tools and/or biomarkers. The novel cannabinergic nitrate ester compounds provide medicaments useful in treating a variety of diseases and medical disorders.

  本技术涉及新型大麻素硝酸酯及其类似物、制备方法、制药组合物及其作为药物、药理工具和/或生物标志物的使用方法。这些新型大麻素硝酸酯化合物提供了治疗各种疾病和医学障碍的有用药物。
• NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF
  申请人：Franklin Richard

  公开号：US20100286186A1

  公开（公告）日：2010-11-11

  The present invention concerns dicarboxylic acid linked amino acid and peptide prodrugs of opioid analgesics and pharmaceutical compositions containing such prodrugs. Methods for providing pain relief, decreasing the adverse GI side effects of the opioid analgesic and increasing the bioavailability of the opioid analgesic with the aforementioned prodrugs are also provided. In one embodiment, prodrugs having the amino acid side chains of valine, leucine, isoleucine and glycine; and mono-, di- and tripeptides thereof are provided.
• MODIFIED POLYMERS FOR DELIVERY OF POLYNUCLEOTIDES, METHOD OF MANUFACTURE, AND METHODS OF USE THEREOF
  申请人：Yurkovetskiy Aleksandr

  公开号：US20110243880A1

  公开（公告）日：2011-10-06

  A polynucleotide delivery vehicle comprising a modified polymer is provided herein, the modified polymer having the following formula: in which W 1 , W 2 , W 3 , W 4 , W 5 , W 6 , Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 9 , R 1 , R 2 , R 3 , R 4 , R 5 , n 1 , n 2 , n 3 , n 4 , n 5 , and n 6 are defined herein. Also disclosed are methods of delivering a polynucleotide to the cytoplasm of a selected tissue type or cell type and methods of reducing expression of a gene in a cell or a subject in need thereof with the modified polymer.